OmniLytics Enters Collaboration with Elanco
SALT LAKE CITY--(BUSINESS WIRE)--OmniLytics, Inc. of Salt Lake City, UT today announced that it has entered into a collaborative research and license agreement with Elanco, a division of Eli Lilly and Company (NYSE: LLY), encompassing a series of products for the treatment of food-borne bacterial pathogens using OmniLytics’ bacteriophage (“phage”) technology.